大博醫療(002901.SZ)擬與合資方胡駿對百齒泰進行同比例增資
格隆匯3月27日丨大博醫療(002901.SZ)公佈,公司於2020年3月26日召開了第二屆董事會第六次會議,審議並通過了《關於向控股子公司增資的議案》,為進一步增強百齒泰(廈門)醫療科技有限公司(“百齒泰”)資本實力及經營規模,提高其整體競爭力,公司擬與合資方胡駿對百齒泰進行同比例增資,其中公司以自有資金增資人民幣4230萬元至4500萬元,胡駿以自有資金增資人民幣470萬元至500萬元。
此次增資完成後,百齒泰的註冊資本由300萬元增至5000萬元,公司仍持有百齒泰90%的股權。
此次增資旨在進一步增強百齒泰的資本實力與綜合競爭力,加強齒科的生產、研發及營銷渠道的建設,加快公司醫用高值耗材領域的佈局。此次增資的事項不會對公司財務及經營狀況產生不利影響,也不存在損害公司及全體股東利益的情況,符合公司發展戰略和長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.